CCL2 and metabolic dysfunction-associated steatohepatitis: Clinical trials on cenicriviroc, a CC-chemokine receptor 2 (CCR2) antagonist, as a means to block CCL2 signaling, have shown significant improvements in relieving fibrosis progression with NASH (17).